Suggested remit - To appraise the clinical and cost effectiveness of lumacaftor in combination with ivacaftor within its marketing authorisation for treating cystic fibrosis in children ages 2 to 11 years old who are homozygous for the F508del mutation
Status Proposed
Process STA 2018
ID number 1486

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
22 August 2019 Draft scope documents
25 September 2018 - 23 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance